首页 > 最新文献

Europace最新文献

英文 中文
Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion? 完善 CHA2DS2VASc 风险分层方案:是否应取消性别类别标准?
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1093/europace/euae280
Hiroyuki Yoshimura, Rui Providencia, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip

Aims: The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score.

Methods and results: We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (-7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status).

Conclusion: Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis.

背景:建议使用 CHA2DS2VASc 评分对心房颤动(房颤)患者进行卒中风险分层。根据本世纪初的证据,女性血栓栓塞风险较高,因此该评分对女性多加一分。在 2007 年至 2018 年期间,女性血栓栓塞风险的这一增量随时间推移而下降,近年来变得不显著:评估从 CHA2DS2VASc 评分中去除性别类别(Sc)的影响,从而验证无性别的 CHA2DS2VASc(即 CHA2DS2VA)评分:我们分析了英国初级和二级医疗数据,其中包括 1998-2016 年间随访的 195,719 名房颤患者(平均年龄:75.9±12.3 岁;49.2% 为女性)。在 126428 名非抗凝患者中,我们比较了每个日历年的 CHA2DS2VASc 与 CHA2DS2VA 评分:在 413 007 个患者年中,共记录了 8 742 例缺血性中风或全身性栓塞事件。在低风险人群中未观察到血栓栓塞风险的性别差异,但在高风险类别(即 CHA2DS2VA ≥2)中,女性患者的中风发生率一直较高。多年来,CHA2DS2VA 和 CHA2DS2VASc 评分的 C 统计量相似(从 0.62 到 0.71 不等)。CHA2DS2VA 在 IDI 中未观察到相关差异,而 NRI 在血栓栓塞风险较低的组别中提高了重新分类率(11%)。NRI 提示血栓栓塞风险较高的患者存在分类错误(-7%),但这并不影响他们的抗凝适应症(即患者仍保持高危状态):结论:将 Sc 从 CHA2DS2VASc 评分中去除并不会影响其对房颤人群血栓栓塞事件的判别能力。使用 CHA2DS2VA 可以简化血栓预防的初步决策。
{"title":"Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?","authors":"Hiroyuki Yoshimura, Rui Providencia, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip","doi":"10.1093/europace/euae280","DOIUrl":"10.1093/europace/euae280","url":null,"abstract":"<p><strong>Aims: </strong>The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score.</p><p><strong>Methods and results: </strong>We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (-7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status).</p><p><strong>Conclusion: </strong>Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study. 心房颤动患者使用抗心律失常疗法的性别和年龄差异:一项全国性队列研究。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae264
Birgitta Salmela, Jussi Jaakkola, Ksenia Kalatsova, Jaakko Inkovaara, Aapo L Aro, Konsta Teppo, Tero Penttilä, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto

Aims: Atrial fibrillation (AF) patients frequently require active rhythm control therapy to maintain sinus rhythm and reduce symptom burden. Our study assessed whether antiarrhythmic therapies (AATs) are used disproportionately between men and women after new-onset AF.

Methods and results: The nationwide Finnish anticoagulation in AF registry-based linkage study covers all patients with new-onset AF in Finland during 2007-2018. Study outcomes included initiation of AATs in the form of antiarrhythmic drugs (AADs), cardioversion, or catheter ablation. The study population constituted of 229 565 patients (50% females). Women were older than men (76.6 ± 11.8 vs. 68.9 ± 13.4 years) and had higher prevalence of hypertension or hyperthyroidism, but lower prevalence of vascular disease, diabetes, renal disease, and cardiomyopathies than men. Overall, 17.6% of women and 25.1% of men were treated with any AAT. Women were treated with AADs more often than men in all age groups [adjusted subdistribution hazard ratio (aSHR) 1.223, 95% confidence interval (CI) 1.187-1.261]. Cardioversions were also performed less often on women than on men aged <65 years (aSHR 0.722, 95% CI 0.695-0.749), more often in patients ≥ 75 years (aSHR 1.166, 95% CI 1.108-1.227), while no difference between the sexes existed in patients aged 65-74 years. Ablations were performed less often in women aged <65 years (aSHR 0.908, 95% CI 0.826-0.998) and ≥75 years (aSHR 0.521, 95% CI 0.354-0.766), whereas there was no difference in patients aged 65-74 years.

Conclusion: Women used more AAD than men in all age groups but underwent fewer cardioversion and ablation procedures when aged <65 years.

背景和目的:心房颤动(房颤)患者经常需要积极的节律控制治疗来维持窦性心律并减轻症状负担。我们的研究评估了新发房颤患者使用抗心律失常疗法(AATs)的比例是否男女有别:方法:全国性的芬兰心房颤动抗凝登记关联研究(FinACAF)涵盖了2007-2018年间芬兰所有新发房颤患者。研究结果包括以抗心律失常药物(AAD)、心脏复律或导管消融的形式开始使用抗心律失常药物:研究对象包括 229 565 名患者(50% 为女性)。女性的年龄比男性大(76.6 ± 11.8 岁对 68.9 ± 13.4 岁),高血压或甲状腺功能亢进的发病率比男性高,但血管疾病、糖尿病、肾病和心肌病的发病率比男性低。总体而言,17.6%的女性和25.1%的男性接受过任何一种AAT治疗。在所有年龄组中,女性接受 AAD 治疗的频率均高于男性(调整后的亚分布危险比(aSHR)为 1.223,95%-CI 为 1.187-1.261)。此外,女性比男性更少进行心脏转复手术:在所有年龄组中,女性比男性使用更多的 AAD,但接受心脏复律和消融手术的人数却比男性少。
{"title":"Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study.","authors":"Birgitta Salmela, Jussi Jaakkola, Ksenia Kalatsova, Jaakko Inkovaara, Aapo L Aro, Konsta Teppo, Tero Penttilä, Olli Halminen, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juha Hartikainen, K E Juhani Airaksinen, Mika Lehto","doi":"10.1093/europace/euae264","DOIUrl":"10.1093/europace/euae264","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) patients frequently require active rhythm control therapy to maintain sinus rhythm and reduce symptom burden. Our study assessed whether antiarrhythmic therapies (AATs) are used disproportionately between men and women after new-onset AF.</p><p><strong>Methods and results: </strong>The nationwide Finnish anticoagulation in AF registry-based linkage study covers all patients with new-onset AF in Finland during 2007-2018. Study outcomes included initiation of AATs in the form of antiarrhythmic drugs (AADs), cardioversion, or catheter ablation. The study population constituted of 229 565 patients (50% females). Women were older than men (76.6 ± 11.8 vs. 68.9 ± 13.4 years) and had higher prevalence of hypertension or hyperthyroidism, but lower prevalence of vascular disease, diabetes, renal disease, and cardiomyopathies than men. Overall, 17.6% of women and 25.1% of men were treated with any AAT. Women were treated with AADs more often than men in all age groups [adjusted subdistribution hazard ratio (aSHR) 1.223, 95% confidence interval (CI) 1.187-1.261]. Cardioversions were also performed less often on women than on men aged <65 years (aSHR 0.722, 95% CI 0.695-0.749), more often in patients ≥ 75 years (aSHR 1.166, 95% CI 1.108-1.227), while no difference between the sexes existed in patients aged 65-74 years. Ablations were performed less often in women aged <65 years (aSHR 0.908, 95% CI 0.826-0.998) and ≥75 years (aSHR 0.521, 95% CI 0.354-0.766), whereas there was no difference in patients aged 65-74 years.</p><p><strong>Conclusion: </strong>Women used more AAD than men in all age groups but underwent fewer cardioversion and ablation procedures when aged <65 years.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial. 挪威心房颤动自我检测试验(NORSCREEN):随机对照试验的原理与设计。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae228
Miroslav Boskovic, Jarle Jortveit, Marius Blørstad Haraldsen, Trygve Berge, Johan Engdahl, Maja-Lisa Løchen, Peter Schuster, Edvard Liljedahl Sandberg, Jostein Grimsmo, Dan Atar, Ole-Gunnar Anfinsen, Are Hugo Pripp, Bjørnar Leangen Grenne, Sigrun Halvorsen

Aims: Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3-7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.

Methods and results: This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3-7 days at home with a patch ECG device (ECG247) at inclusion and after 12-18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023.

Conclusion: The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.

Trial registration: Clinical trials: NCT05914883.

背景和目的:心房颤动(房颤)是一种常见的心律失常,许多病例可能无法确诊。筛查心房颤动并在发现心房颤动后进行治疗是否能改善长期预后,目前尚无定论。挪威心房颤动自我筛查试验(NORSCREEN)的主要目的是评估在 65 岁或以上、至少有一个额外中风风险因素的人群中进行为期 3-7 天的连续心电图心房颤动自我筛查,并对检测出心房颤动的患者启动指南推荐的治疗,是否能减少中风的发生:该研究是一项全国范围的随机、开放、无坐位对照试验。从挪威国家人口登记册中随机确定年龄≥65 岁的个人,并邀请他们参加数字纳入/排除测试。通过包容性/排斥性测试的人将被随机分配到干预组或对照组。总共将有 35000 名参与者参加。干预组在纳入时和 12-18 个月后连续 3-7 天在家使用贴片式心电图设备 (ECG247) 进行自我筛查。如果检测到房颤,将启动指南推荐的治疗。将通过国家健康登记处对患者进行为期五年的随访。主要结果是中风发生时间。NORSCREEN 试验的首位参与者于 2023 年 9 月 1 日注册:NORSCREEN试验的结果将为数字无坐位房颤自我筛查在预防中风高危人群中的疗效提供新的见解。
{"title":"The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial.","authors":"Miroslav Boskovic, Jarle Jortveit, Marius Blørstad Haraldsen, Trygve Berge, Johan Engdahl, Maja-Lisa Løchen, Peter Schuster, Edvard Liljedahl Sandberg, Jostein Grimsmo, Dan Atar, Ole-Gunnar Anfinsen, Are Hugo Pripp, Bjørnar Leangen Grenne, Sigrun Halvorsen","doi":"10.1093/europace/euae228","DOIUrl":"10.1093/europace/euae228","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3-7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.</p><p><strong>Methods and results: </strong>This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3-7 days at home with a patch ECG device (ECG247) at inclusion and after 12-18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023.</p><p><strong>Conclusion: </strong>The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.</p><p><strong>Trial registration: </strong>Clinical trials: NCT05914883.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early rapid local impedance drop is associated with acute lesion efficacy during pulmonary vein isolation. 肺静脉隔离术中,早期局部阻抗快速下降与急性病变疗效有关。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae260
Péter Perge, Nikola Petrovic, Zoltán Salló, Katalin Piros, Vivien Klaudia Nagy, Pál Ábrahám, István Osztheimer, Béla Merkely, László Gellér, Nándor Szegedi

Aims: The predictive role of local impedance (LI) drop in lesion formation using a novel contact force sensing ablation catheter was recently described. The purpose of our current study was to assess the temporal characteristics of LI drop during ablation and its correlation with acute lesion efficacy.

Methods and results: Point-by-point pulmonary vein isolation was performed. The efficacy of applications was determined by pacing along the circular ablation line and assessing loss of capture. Local impedance, contact force, and catheter position data with high resolution were analysed and compared in successful and unsuccessful applications. Five hundred and fifty-nine successful and 84 unsuccessful applications were analysed. The successful applications showed higher baseline LI (P < 0.001) and larger LI drop during ablation (P < 0.001, for all). In case of unsuccessful applications, after a moderate but significant drop from baseline to the 2 s time point (153 vs. 145 Ω, P < 0.001), LI did not change further (P = 0.99). Contradictorily, in case of successful applications, the LI significantly decreased further (baseline-2 s-10 s: 161-150-141 Ω, P < 0.001 for all). The optimal cut-point for the LI drop indicating unsuccessful application was <9 Ω at the 4-s time point [AUC = 0.73 (0.67-0.76), P < 0.001]. Failing to reach this cut-point predicted unsuccessful applications [OR 3.82 (2.34-6.25); P < 0.001].

Conclusion: A rapid and enduring drop of the LI may predict effective lesion formation, while slightly changing or unchanged LI is associated with unsuccessful applications. A moderate LI drop during the first 4 s of radiofrequency application predicts ineffective radiofrequency delivery.

导言:最近描述了使用新型接触力传感消融导管时局部阻抗下降对病灶形成的预测作用。我们本次研究的目的是评估消融过程中局部阻抗下降的时间特征及其与急性病变疗效的相关性:方法:进行逐点肺静脉隔离。方法:进行逐点肺静脉隔离,通过沿环形消融线起搏和评估捕获损失来确定应用效果。分析并比较了成功和失败应用中的高分辨率局部阻抗、接触力和导管位置数据:结果:分析了 559 次成功应用和 84 次失败应用。结果:对 559 次成功应用和 84 次失败应用进行了分析。成功应用显示出较高的基线局部阻抗(pConclusion):局部阻抗快速而持久的下降可能预示着病灶的有效形成,而局部阻抗的轻微变化或不变与不成功的应用有关。在射频应用的最初 4 秒内,局部阻抗适度下降预示着射频传输效果不佳。
{"title":"Early rapid local impedance drop is associated with acute lesion efficacy during pulmonary vein isolation.","authors":"Péter Perge, Nikola Petrovic, Zoltán Salló, Katalin Piros, Vivien Klaudia Nagy, Pál Ábrahám, István Osztheimer, Béla Merkely, László Gellér, Nándor Szegedi","doi":"10.1093/europace/euae260","DOIUrl":"10.1093/europace/euae260","url":null,"abstract":"<p><strong>Aims: </strong>The predictive role of local impedance (LI) drop in lesion formation using a novel contact force sensing ablation catheter was recently described. The purpose of our current study was to assess the temporal characteristics of LI drop during ablation and its correlation with acute lesion efficacy.</p><p><strong>Methods and results: </strong>Point-by-point pulmonary vein isolation was performed. The efficacy of applications was determined by pacing along the circular ablation line and assessing loss of capture. Local impedance, contact force, and catheter position data with high resolution were analysed and compared in successful and unsuccessful applications. Five hundred and fifty-nine successful and 84 unsuccessful applications were analysed. The successful applications showed higher baseline LI (P < 0.001) and larger LI drop during ablation (P < 0.001, for all). In case of unsuccessful applications, after a moderate but significant drop from baseline to the 2 s time point (153 vs. 145 Ω, P < 0.001), LI did not change further (P = 0.99). Contradictorily, in case of successful applications, the LI significantly decreased further (baseline-2 s-10 s: 161-150-141 Ω, P < 0.001 for all). The optimal cut-point for the LI drop indicating unsuccessful application was <9 Ω at the 4-s time point [AUC = 0.73 (0.67-0.76), P < 0.001]. Failing to reach this cut-point predicted unsuccessful applications [OR 3.82 (2.34-6.25); P < 0.001].</p><p><strong>Conclusion: </strong>A rapid and enduring drop of the LI may predict effective lesion formation, while slightly changing or unchanged LI is associated with unsuccessful applications. A moderate LI drop during the first 4 s of radiofrequency application predicts ineffective radiofrequency delivery.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing SARS-CoV-2 viroporins with antiarrhythmic drugs. 用抗心律失常药物治疗 SARS-CoV-2 病毒。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae254
Meye Bloothooft, Niels Voigt, Teun P de Boer
{"title":"Addressing SARS-CoV-2 viroporins with antiarrhythmic drugs.","authors":"Meye Bloothooft, Niels Voigt, Teun P de Boer","doi":"10.1093/europace/euae254","DOIUrl":"https://doi.org/10.1093/europace/euae254","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 10","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bipolar radiofrequency ablation of refractory ventricular arrhythmias: results from a multicentre network. 难治性室性心律失常的双极射频消融术:多中心网络的研究结果
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae248
Piotr Futyma, Arian Sultan, Łukasz Zarębski, Guram Imnadze, Vera Maslova, Stefano Bordignon, Maria Kousta, Sven Knecht, Nikola Pavlović, Petr Peichl, Evgeny Lian, Thomas Kueffer, Daniel Scherr, Michael Pfeffer, Paweł Moskal, Gabriel Cismaru, Bor Antolič, Paweł Wałek, Shaojie Chen, Martin Martinek, Georgios Kollias, Michael Derndorfer, Sebastian Seidl, Boris Schmidt, Jakob Lüker, Daniel Steven, Philipp Sommer, Marek Jastrzębski, Josef Kautzner, Tobias Reichlin, Christian Sticherling, Helmut Pürerfellner, Andres Enriquez, Jonas Wörmann, Julian K R Chun

Aims: Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular complexes (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT and PVC. Multicentre registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking. The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.

Methods and results: Consecutive patients undergoing Bi-RFA at 16 European centres for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target. Between March 2021 and August 2024, 91 patients underwent 94 Bi-RFA procedures (74 males, age 62 ± 13, and prior Uni-RFA range 1-8). Indications were recurrence of PVC (n = 56), VT (n = 20), electrical storm (n = 13), or PVC-triggered ventricular fibrillation (n = 2). Procedural time was 160 ± 73 min, Bi-RFA time 426 ± 286 s, and mean Uni-RFA time 819 ± 697 s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients and suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%), no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, atrioventricular block, and arteriovenous fistula. Follow-up lasted 7 ± 8 months. Nineteen patients (61%) remained VT free. ≥80% PVC burden reduction was achieved in 45 (78%).

Conclusion: These real-world registry data indicate that Bi-RFA appears safe, is feasible, and is effective in the majority of patients with VT/PVC.

背景:治疗标准单极射频消融术(Uni-RFA)难治性室速(VT)和室性早搏(PVC)需要先进的消融策略。双极射频导管消融术(Bi-RFA)已成为难治性 VT 和 PVC 的一种治疗选择。目的:本 Bi-RFA 登记旨在确定其在难治性 VT/PVC 患者中的实际安全性、可行性和疗效:方法:纳入在 16 个欧洲中心接受 Bi-RFA 治疗的至少一次标准 Uni-RFA 后复发 VT/PVC 的连续患者。使用第二根消融导管代替分散贴片,并将导管放置在消融目标的相反部位:2021年3月至2024年8月期间,91名患者接受了94次Bi-RFA手术(74名男性,年龄62±13岁,之前接受过Uni-RFA的患者范围为1-8)。适应症为 PVC 复发(56 例)、VT(20 例)、电风暴(13 例)或 PVC 触发的室颤(2 例)。手术时间为 160±73 分钟,Bi-RFA 时间为 426±286 秒,Uni-RFA 平均时间为 819±697 秒。67 例(74%)患者消除了临床 VT/PVC,另有 10 例(11%)患者抑制了 VT/PVC。其余 14 名患者(15%)未观察到对 VT/PVC 的影响。出现了三种主要并发症:冠状动脉闭塞、房室传导阻滞和动静脉瘘。随访时间为 7±8 个月。19名患者(61%)仍无VT,45名患者(78%)的PVC负荷减少≥80%:这项真实世界登记数据表明,Bi-RFA 对大多数 VT/PVC 患者是安全、可行和有效的。
{"title":"Bipolar radiofrequency ablation of refractory ventricular arrhythmias: results from a multicentre network.","authors":"Piotr Futyma, Arian Sultan, Łukasz Zarębski, Guram Imnadze, Vera Maslova, Stefano Bordignon, Maria Kousta, Sven Knecht, Nikola Pavlović, Petr Peichl, Evgeny Lian, Thomas Kueffer, Daniel Scherr, Michael Pfeffer, Paweł Moskal, Gabriel Cismaru, Bor Antolič, Paweł Wałek, Shaojie Chen, Martin Martinek, Georgios Kollias, Michael Derndorfer, Sebastian Seidl, Boris Schmidt, Jakob Lüker, Daniel Steven, Philipp Sommer, Marek Jastrzębski, Josef Kautzner, Tobias Reichlin, Christian Sticherling, Helmut Pürerfellner, Andres Enriquez, Jonas Wörmann, Julian K R Chun","doi":"10.1093/europace/euae248","DOIUrl":"10.1093/europace/euae248","url":null,"abstract":"<p><strong>Aims: </strong>Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular complexes (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT and PVC. Multicentre registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking. The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.</p><p><strong>Methods and results: </strong>Consecutive patients undergoing Bi-RFA at 16 European centres for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target. Between March 2021 and August 2024, 91 patients underwent 94 Bi-RFA procedures (74 males, age 62 ± 13, and prior Uni-RFA range 1-8). Indications were recurrence of PVC (n = 56), VT (n = 20), electrical storm (n = 13), or PVC-triggered ventricular fibrillation (n = 2). Procedural time was 160 ± 73 min, Bi-RFA time 426 ± 286 s, and mean Uni-RFA time 819 ± 697 s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients and suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%), no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, atrioventricular block, and arteriovenous fistula. Follow-up lasted 7 ± 8 months. Nineteen patients (61%) remained VT free. ≥80% PVC burden reduction was achieved in 45 (78%).</p><p><strong>Conclusion: </strong>These real-world registry data indicate that Bi-RFA appears safe, is feasible, and is effective in the majority of patients with VT/PVC.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular haemolysis and acute kidney injury following atrial fibrillation ablation: a report using two different systems for pulsed field ablation. 心房颤动消融术后的血管内溶血和急性肾损伤:一份使用两种不同系统进行脉冲场消融的报告。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae251
Maarten A J De Smet, Clara François, Benjamin De Becker, Rene Tavernier, Jean-Benoît le Polain de Waroux, Sébastien Knecht, Mattias Duytschaever
{"title":"Intravascular haemolysis and acute kidney injury following atrial fibrillation ablation: a report using two different systems for pulsed field ablation.","authors":"Maarten A J De Smet, Clara François, Benjamin De Becker, Rene Tavernier, Jean-Benoît le Polain de Waroux, Sébastien Knecht, Mattias Duytschaever","doi":"10.1093/europace/euae251","DOIUrl":"10.1093/europace/euae251","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multielectrode catheter-based pulsed field ablation of persistent and long-standing persistent atrial fibrillation. 基于多电极导管的脉冲场消融持续性和长期持续性心房颤动。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae246
Domenico G Della Rocca, Antonio Sorgente, Luigi Pannone, María Cespón-Fernández, Giampaolo Vetta, Alexandre Almorad, Gezim Bala, Alvise Del Monte, Erwin Ströker, Juan Sieira, Ioannis Doundoulakis, Sahar Mouram, Charles Audiat, Cinzia Monaco, Sanghamitra Mohanty, Roberto Scacciavillani, Lorenzo Marcon, Kazutaka Nakasone, Wael Zaher, Ingrid Overeinder, Serge Boveda, Mark La Meir, Andrea Natale, Andrea Sarkozy, Carlo de Asmundis, Gian-Battista Chierchia

Aims: Rhythm control of non-paroxysmal atrial fibrillation (AF) is significantly more challenging, as a result of arrhythmia perpetuation promoting atrial substrate changes and AF maintenance. We describe a tailored ablation strategy targeting multiple left atrial (LA) sites via a pentaspline pulsed field ablation (PFA) catheter in persistent AF sustained beyond 6 months (PerAF > 6 m) and long-standing persistent AF (LSPAF).

Methods and results: The ablation protocol included the following stages: pulmonary vein antral and posterior wall isolation plus anterior roof line ablation (Stage 1); electrogram-guided substrate ablation (Stage 2); atrial tachyarrhythmia regionalization and ablation (Stage 3). Seventy-two [age:68 ± 10years, 61.1%males; AF history: 25 (18-45) months] patients with PerAF > 6 m (52.8%) and LSPAF (47.2%) underwent their first PFA via the FarapulseTM system. LA substrate ablation (Stage 1 and 2) led to AF termination in 95.8% of patients. AF organized into a left-sided atrial flutter (AFlu) in 46 (74.2%) patients. The PFA catheter was used to identify LA sites showing diastolic, low-voltage electrograms and entrainment from its splines was performed to confirm the pacing site was inside the AFlu circuit. Left AFlu termination was achieved in all cases via PFA delivery. Total procedural and LA dwell times were 112 ± 25 min and 59 ± 22 min, respectively. Major complications occurred in 2 (2.8%) patients. Single-procedure success rate was 74.6% after 14.9 ± 2.7 months of follow-up; AF-free survival was 89.2%.

Conclusion: In our cohort, PFA-based AF substrate ablation led to AF termination in 95.8% of cases. Very favourable clinical outcomes were observed during >1 year of follow-up.

背景和目的:非阵发性心房颤动(房颤)的节律控制明显更具挑战性,因为心律失常的持续会促进心房底质的改变和房颤的维持。我们介绍了针对持续房颤超过 6 个月(PerAF>6m)和长期持续房颤(LSPAF),通过五线脉冲场消融(PFA)导管针对多个左心房(LA)部位的定制消融策略:消融方案包括以下阶段:肺静脉前壁和后壁隔离加前顶线消融(第1阶段);电图引导下的基底消融(第2阶段);心房快速性心律失常区域化和消融(第3阶段):72名[年龄:68±10岁,61.1%男性;房颤病史:25(18-45)个月]PerAF>6m(52.8%)和LSPAF(47.2%)患者通过FarapulseTM系统接受了首次PFA。95.8%的患者通过 LA 基底消融(1 期和 2 期)终止了房颤。有 46 名患者(74.2%)的房颤发展为左心房扑动(AFlu)。使用 PFA 导管确定显示舒张期低电压电图的 LA 位点,并对其花键进行夹带,以确认起搏位点位于 AFlu 回路内。所有病例均通过 PFA 输送实现左房颤终止。手术总时间和 LA 驻留时间分别为 112±25 分钟和 59±22 分钟。2例(2.8%)患者出现了严重并发症。随访14.9±2.7个月后,单次手术成功率为74.6%;无房颤生存率为89.2%:在我们的队列中,95.8%的病例通过基于PFA的房颤基底消融术终止了房颤。在超过一年的随访中观察到了非常良好的临床结果。
{"title":"Multielectrode catheter-based pulsed field ablation of persistent and long-standing persistent atrial fibrillation.","authors":"Domenico G Della Rocca, Antonio Sorgente, Luigi Pannone, María Cespón-Fernández, Giampaolo Vetta, Alexandre Almorad, Gezim Bala, Alvise Del Monte, Erwin Ströker, Juan Sieira, Ioannis Doundoulakis, Sahar Mouram, Charles Audiat, Cinzia Monaco, Sanghamitra Mohanty, Roberto Scacciavillani, Lorenzo Marcon, Kazutaka Nakasone, Wael Zaher, Ingrid Overeinder, Serge Boveda, Mark La Meir, Andrea Natale, Andrea Sarkozy, Carlo de Asmundis, Gian-Battista Chierchia","doi":"10.1093/europace/euae246","DOIUrl":"10.1093/europace/euae246","url":null,"abstract":"<p><strong>Aims: </strong>Rhythm control of non-paroxysmal atrial fibrillation (AF) is significantly more challenging, as a result of arrhythmia perpetuation promoting atrial substrate changes and AF maintenance. We describe a tailored ablation strategy targeting multiple left atrial (LA) sites via a pentaspline pulsed field ablation (PFA) catheter in persistent AF sustained beyond 6 months (PerAF > 6 m) and long-standing persistent AF (LSPAF).</p><p><strong>Methods and results: </strong>The ablation protocol included the following stages: pulmonary vein antral and posterior wall isolation plus anterior roof line ablation (Stage 1); electrogram-guided substrate ablation (Stage 2); atrial tachyarrhythmia regionalization and ablation (Stage 3). Seventy-two [age:68 ± 10years, 61.1%males; AF history: 25 (18-45) months] patients with PerAF > 6 m (52.8%) and LSPAF (47.2%) underwent their first PFA via the FarapulseTM system. LA substrate ablation (Stage 1 and 2) led to AF termination in 95.8% of patients. AF organized into a left-sided atrial flutter (AFlu) in 46 (74.2%) patients. The PFA catheter was used to identify LA sites showing diastolic, low-voltage electrograms and entrainment from its splines was performed to confirm the pacing site was inside the AFlu circuit. Left AFlu termination was achieved in all cases via PFA delivery. Total procedural and LA dwell times were 112 ± 25 min and 59 ± 22 min, respectively. Major complications occurred in 2 (2.8%) patients. Single-procedure success rate was 74.6% after 14.9 ± 2.7 months of follow-up; AF-free survival was 89.2%.</p><p><strong>Conclusion: </strong>In our cohort, PFA-based AF substrate ablation led to AF termination in 95.8% of cases. Very favourable clinical outcomes were observed during >1 year of follow-up.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detailed analysis of electrogram peak frequency to guide ventricular tachycardia substrate mapping. 详细分析心电图峰值频率,指导室性心动过速基底图绘制。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae253
Joseph Mayer, Jaffar Al-Sheikhli, Maria Niespialowska-Steuden, Ian Patchett, James Winter, Rafaella Siang, Nicolas Lellouche, Karthick Manoharan, Thanh Trung Phan, Justo Juliá Calvo, Andreu Porta-Sánchez, Ivo Roca Luque, John Silberbauer, Tarvinder Dhanjal

Aims: Differentiating near-field (NF) and far-field (FF) electrograms (EGMs) is crucial in identifying critical arrhythmogenic substrate during ventricular tachycardia (VT) ablation. A novel algorithm annotates NF-fractionated signals enabling EGM peak frequency (PF) determination using wavelet transformation. This study evaluated the algorithms' effectiveness in identifying critical components of the VT circuit during substrate mapping.

Methods and results: A multicentre, international cohort undergoing VT ablation was investigated. VT activation maps were used to demarcate the isthmus zone (IZ). Offline analysis was performed to evaluate the diagnostic performance of low-voltage area (LVA) PF substrate mapping. A total of 30 patients encompassing 198 935 EGMs were included. The IZ PF was significantly higher in sinus rhythm (SR) compared to right ventricular paced (RVp) substrate maps (234 Hz (195-294) vs. 197 Hz (166-220); P = 0.010). Compared to LVA PF, the IZ PF was significantly higher in both SR and RVp substrate maps (area under curve, AUC: 0.74 and 0.70, respectively). The LVA PF threshold of ≥200 Hz was optimal in SR maps (sensitivity 69%; specificity 64%) and RVp maps (sensitivity 60%; specificity 64%) in identifying the VT isthmus. In amiodarone-treated patients (n = 20), the SR substrate map IZ PF was significantly lower (222 Hz (186-257) vs. 303 Hz (244-375), P = 0.009) compared to amiodarone-naïve patients (n = 10). The ≥200 Hz LVA PF threshold resulted in an 80% freedom from VT with a trend towards reduced ablation lesions and radiofrequency times.

Conclusion: LVA PF substrate mapping identifies critical components of the VT circuit with an optimal threshold of ≥200 Hz. Isthmus PF is influenced by chronic amiodarone therapy with lower values observed during RV pacing.

背景:在室性心动过速(VT)消融过程中,区分近场(NF)和远场(FF)电图(EGM)对于识别关键致心律失常基质至关重要。一种新型算法可注释 NF 分馏信号,从而利用小波变换确定 EGM 峰频 (PF)。本研究评估了该算法在底物映射过程中识别 VT 电路关键组件的有效性:研究对象是接受 VT 消融术的多中心国际队列。VT 激活图用于划分峡部区(IZ)。进行离线分析以评估低电压区(LVA)PF 基底图的诊断性能:结果:共纳入了 30 名患者,共绘制了 198,935 个 EGMs。与右室起搏(RVp)基底图相比,窦性心律(SR)的 IZ PF 明显更高(234(195-294)Hz vs 197(166-220)Hz;P=0.010)。与 LVA PF 相比,SR 和 RVp 基底图中的 IZ PF 明显更高(AUC:分别为 0.74 和 0.70)。在 SR 基底图(灵敏度 69%;特异性 64%)和 RVp 基底图(灵敏度 60%;特异性 64%)中,≥200Hz 的 LVA PF 阈值是识别 VT 峡部的最佳阈值。在胺碘酮治疗的患者中(n=20),SR 基底图 IZ PF 与胺碘酮无效的患者(n=10)相比显著降低(222(186-257)Hz vs 303(244-375)Hz,p=0.009)。≥200Hz的LVA PF阈值可使80%的患者免于VT,并有减少消融病灶和射频时间的趋势:结论:LVA PF基底映射可识别VT电路的关键组成部分,其最佳阈值为≥200Hz。地峡 PF 受长期胺碘酮治疗的影响,在 RV 起搏时观察到的数值较低。
{"title":"Detailed analysis of electrogram peak frequency to guide ventricular tachycardia substrate mapping.","authors":"Joseph Mayer, Jaffar Al-Sheikhli, Maria Niespialowska-Steuden, Ian Patchett, James Winter, Rafaella Siang, Nicolas Lellouche, Karthick Manoharan, Thanh Trung Phan, Justo Juliá Calvo, Andreu Porta-Sánchez, Ivo Roca Luque, John Silberbauer, Tarvinder Dhanjal","doi":"10.1093/europace/euae253","DOIUrl":"10.1093/europace/euae253","url":null,"abstract":"<p><strong>Aims: </strong>Differentiating near-field (NF) and far-field (FF) electrograms (EGMs) is crucial in identifying critical arrhythmogenic substrate during ventricular tachycardia (VT) ablation. A novel algorithm annotates NF-fractionated signals enabling EGM peak frequency (PF) determination using wavelet transformation. This study evaluated the algorithms' effectiveness in identifying critical components of the VT circuit during substrate mapping.</p><p><strong>Methods and results: </strong>A multicentre, international cohort undergoing VT ablation was investigated. VT activation maps were used to demarcate the isthmus zone (IZ). Offline analysis was performed to evaluate the diagnostic performance of low-voltage area (LVA) PF substrate mapping. A total of 30 patients encompassing 198 935 EGMs were included. The IZ PF was significantly higher in sinus rhythm (SR) compared to right ventricular paced (RVp) substrate maps (234 Hz (195-294) vs. 197 Hz (166-220); P = 0.010). Compared to LVA PF, the IZ PF was significantly higher in both SR and RVp substrate maps (area under curve, AUC: 0.74 and 0.70, respectively). The LVA PF threshold of ≥200 Hz was optimal in SR maps (sensitivity 69%; specificity 64%) and RVp maps (sensitivity 60%; specificity 64%) in identifying the VT isthmus. In amiodarone-treated patients (n = 20), the SR substrate map IZ PF was significantly lower (222 Hz (186-257) vs. 303 Hz (244-375), P = 0.009) compared to amiodarone-naïve patients (n = 10). The ≥200 Hz LVA PF threshold resulted in an 80% freedom from VT with a trend towards reduced ablation lesions and radiofrequency times.</p><p><strong>Conclusion: </strong>LVA PF substrate mapping identifies critical components of the VT circuit with an optimal threshold of ≥200 Hz. Isthmus PF is influenced by chronic amiodarone therapy with lower values observed during RV pacing.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study. 心力衰竭患者心脏再同步装置的全面远程监控与标准远程监控:ECOST-CRT 研究结果。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-03 DOI: 10.1093/europace/euae233
Cédric Klein, Claude Kouakam, Arnaud Lazarus, Pascal de Groote, Christophe Bauters, Eloi Marijon, Frédéric Mouquet, Bruno Degand, Yves Guyomar, Jacques Mansourati, Christophe Leclercq, Laurence Guédon-Moreau

Aims: Integrating remote monitoring (RM) into existing healthcare practice for heart failure (HF) patients to improve clinical outcome remains challenging. The ECOST-CRT study compared the clinical outcome of a comprehensive RM scheme including a patient questionnaire capturing signs and symptoms of HF and notifications for HF specific parameters to traditional RM in patients with cardiac resynchronization therapy (CRT) devices.

Methods and results: Patients were randomized 1:1 to standard daily RM (notification for technical parameters and ventricular arrhythmias; control group) or comprehensive RM (adding a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias; active group). The primary endpoint was all-cause mortality or hospitalization for worsening HF (WHF). Six hundred fifty-two patients (70.4 ± 10.3 years, 73% men, left ventricular ejection fraction 29.1 ± 7.6%, 68% CRT-Defibrillators, 32% CRT-Pacemakers) were enrolled. The COVID-19 pandemic caused an early termination of the study, so the mean follow-up duration was 18 ± 8 months. No statistically significant difference in the primary endpoint was found between the groups [59 (18.3%) control vs. 77 (23.3%) active group; log-rank test P = 0.13]. Among the secondary endpoints, the MLHF questionnaire showed a larger share of patients with improvement of quality of life compared to baseline in the active group (78%) vs. control (61%; P = 0.03).

Conclusion: The study does not support the notion that comprehensive RM, when compared to standard RM, in HF patients with CRT improves the clinical outcome of all-cause mortality or WHF hospitalizations. However, this study was underpowered due to an early termination and further trials are required.

Registration: Clinical Trials.gov Identifier: NCT03012490.

目的:将远程监控(RM)纳入心力衰竭(HF)患者的现有医疗实践以改善临床效果仍具有挑战性。ECOST-CRT 研究比较了综合 RM 方案的临床疗效,该方案包括捕捉心衰体征和症状的患者调查问卷以及心衰特定参数通知,与传统 RM 相比,该方案适用于使用心脏再同步化治疗(CRT)设备的患者:患者按 1:1 随机分配到标准每日 RM(通知技术参数和室性心律失常;对照组)或综合 RM(增加每月症状问卷和双室起搏、室性早搏、房性心律失常通知;积极组)。主要终点是全因死亡率或因高血压恶化住院(WHF)。652 名患者(70.4 ± 10.3 岁,73% 为男性,左心室射血分数 29.1 ± 7.6%,68% 使用 CRT 除颤器,32% 使用 CRT 起搏器)加入了该研究。COVID-19大流行导致研究提前结束,因此平均随访时间为(18±8)个月。在主要终点方面,两组之间没有发现明显的统计学差异[59(18.3%)对照组 vs. 77(23.3%)活动组;对数秩检验 P = 0.13]。在次要终点中,MLHF问卷显示,与基线相比,积极组(78%)与对照组(61%;P = 0.03)中生活质量得到改善的患者比例更大:本研究并不支持这样的观点,即与标准 RM 相比,对使用 CRT 的 HF 患者进行综合 RM 可改善全因死亡率或 WHF 住院率的临床结果。然而,由于研究提前结束,这项研究的影响力不足,因此还需要进一步的试验:注册:Clinical Trials.gov Identifier:NCT03012490。
{"title":"Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.","authors":"Cédric Klein, Claude Kouakam, Arnaud Lazarus, Pascal de Groote, Christophe Bauters, Eloi Marijon, Frédéric Mouquet, Bruno Degand, Yves Guyomar, Jacques Mansourati, Christophe Leclercq, Laurence Guédon-Moreau","doi":"10.1093/europace/euae233","DOIUrl":"https://doi.org/10.1093/europace/euae233","url":null,"abstract":"<p><strong>Aims: </strong>Integrating remote monitoring (RM) into existing healthcare practice for heart failure (HF) patients to improve clinical outcome remains challenging. The ECOST-CRT study compared the clinical outcome of a comprehensive RM scheme including a patient questionnaire capturing signs and symptoms of HF and notifications for HF specific parameters to traditional RM in patients with cardiac resynchronization therapy (CRT) devices.</p><p><strong>Methods and results: </strong>Patients were randomized 1:1 to standard daily RM (notification for technical parameters and ventricular arrhythmias; control group) or comprehensive RM (adding a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias; active group). The primary endpoint was all-cause mortality or hospitalization for worsening HF (WHF). Six hundred fifty-two patients (70.4 ± 10.3 years, 73% men, left ventricular ejection fraction 29.1 ± 7.6%, 68% CRT-Defibrillators, 32% CRT-Pacemakers) were enrolled. The COVID-19 pandemic caused an early termination of the study, so the mean follow-up duration was 18 ± 8 months. No statistically significant difference in the primary endpoint was found between the groups [59 (18.3%) control vs. 77 (23.3%) active group; log-rank test P = 0.13]. Among the secondary endpoints, the MLHF questionnaire showed a larger share of patients with improvement of quality of life compared to baseline in the active group (78%) vs. control (61%; P = 0.03).</p><p><strong>Conclusion: </strong>The study does not support the notion that comprehensive RM, when compared to standard RM, in HF patients with CRT improves the clinical outcome of all-cause mortality or WHF hospitalizations. However, this study was underpowered due to an early termination and further trials are required.</p><p><strong>Registration: </strong>Clinical Trials.gov Identifier: NCT03012490.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 10","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Europace
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1